癲癇治療市場：依癲癇類型、藥物、給藥途徑、年齡層、通路和地區分類

預計到 2026 年，癲癇治療市場規模將達到 115 億美元，到 2033 年將達到 169.5 億美元。預計從 2026 年到 2033 年，該市場將以 5.7% 的複合年成長率成長。

癲癇是一種慢性非傳染性疾病，其特徵是反覆發作的癲癇，表現為短暫的非自主運動，可影響身體的部分或全部。症狀包括大腦中異常的放電活動，這些活動會引發癲癇發作。雖然癲癇可影響任何年齡層的人群，但在兒童和老年人中尤其常見。目前尚無治癒癲癇的根治性，但在約70%的病例中，可以透過藥物控制癲癇發作。全球癲癇治療市場的主要驅動力是全球癲癇盛行率的不斷上升。正在研發的新藥帶來的治療方案的進步也推動了市場成長。

市場動態

全球癲癇治療市場的成長主要受全球癲癇盛行率上升的驅動。根據世界衛生組織（WHO）估計，到2022年，全球將有超過5,000萬人患有癲癇。各國醫療保健支出的增加也為市場帶來了機會。然而，重磅藥物專利到期以及部分學名藥價格下降可能會抑制市場成長。針對難治性癲癇的新療法的研發也為市場成長提供了契機。

本研究的關鍵特徵

• 本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
• 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
• 本研究根據以下參數創建了全球癲癇治療市場主要公司的概況：公司概況、產品系列、主要亮點、財務表現和策略。
• 透過利用本報告中的見解，企業行銷負責人和經營團隊可以就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
• 全球癲癇治療市場報告的目標受群眾外包括該行業的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
• 相關人員可以透過利用分析全球癲癇治療市場中使用的各種策略矩陣，更輕鬆地做出決策。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要

第3章：市場動態、監管與趨勢分析

• 市場動態
• 影響分析
• 監管趨勢
• 產品上市及核准
• PEST分析
• 波特的分析
• 併購情景
• 流行病學
• 管道分析

第4章 癲癇治療市場：依癲癇類型分類，2021-2033年

• 局部性癲癇
• 整體癲癇
• 反射性癲癇
• 其他（進行性性肌陣攣性癲癇等）

第5章 癲癇治療市場：依藥物分類，2021-2033年

• 第一代
• 第二代
• 第三代

第6章 癲癇治療市場：依給藥途徑分類，2021-2033年

• 口服
• 注射藥物
• 其他（鼻腔等）

第7章 癲癇治療市場：依年齡層別分類，2021-2033年

• 兒童
• 成人
• 老年人

第8章 癲癇治療市場：依通路分類，2021-2033年

• 醫院藥房
• 零售藥房
• 網路藥房

第9章 癲癇治療市場：依地區分類，2021-2033年

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲國家
• 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太國家
• 中東
  • GCC
  • 以色列
  • 其他中東國家
• 非洲
  • 南非
  • 北非
  • 中非

第10章 競爭格局

• Pfizer Inc.
• Sumitomo Pharma Co., Ltd.
• Novartis AG
• Abbott
• GSK plc.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Takeda Pharmaceutical Company Limited
• Marinus Pharmaceuticals, Inc
• Eisai Co., Ltd
• DAIICHI SANKYO COMPANY, LIMITED
• Mylan NV
• Reddy's Laboratories Ltd
• Sun Pharmaceutical Industries Ltd.
• Neurelis, Inc.
• Supernus Pharmaceuticals, Inc.

第11章 分析師建議

• 機會分析
• 一致的機會地圖

第12章 參考文獻與調查方法

• 參考
• 調查方法
• 關於本公司

Epilepsy Drugs Market is estimated to be valued at USD 11.50 Bn in 2026 and is expected to reach USD 16.95 Bn by 2033, growing at a compound annual growth rate (CAGR) of 5.7% from 2026 to 2033.

Epilepsy is a chronic non-communicable disease characterized by recurrent seizures, which are brief episodes of involuntary movement that may involve a part of the body or the entire body. Its symptoms include abnormal electrical discharges in the brain causing seizures. It affects people of all ages but is more common in children and older adults. There is no cure for epilepsy but seizures can be controlled in about 70% of cases with medication. The global epilepsy drugs market is primarily driven by the increasing prevalence of epilepsy worldwide. Advancements in the treatment options with new drugs in the pipeline also support the growth of this market.

Market Dynamics

Global epilepsy drugs market growth is primarily driven by increasing prevalence of epilepsy worldwide. In 2022, it was estimated that over 50 million people have epilepsy globally according to the World Health Organization. The market also witnesses opportunities due to the rising healthcare expenditures across various countries. However, the market growth can be restrained by the expiry of patents of blockbuster drugs and price erosion faced by some generic drugs. The development of novel drugs for treatment-resistant epilepsy also presents growth opportunities in the market.

Key Features of the Study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global epilepsy drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Pfizer Inc., Sumitomo Pharma Co., Ltd., Novartis AG, Abbott, GSK plc., Teva Pharmaceutical Industries Ltd., Sanofi, Takeda Pharmaceutical Company Limited, Marinus Pharmaceuticals, Inc, Eisai Co., Ltd, DAIICHI SANKYO COMPANY, LIMITED, Mylan N.V., Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Ltd., Neurelis, Inc., and Supernus Pharmaceuticals, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global epilepsy drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global epilepsy drugs market

Market Segmentation

• Type of Epilepsy Insights (Revenue, USD Bn, 2021 - 2033)
• Focal Epilepsy
• Generalized Epilepsy
• Reflex Epilepsy
• Others (Progressive Myoclonic Epilepsy, etc.)
• Drugs Insights (Revenue, USD Bn, 2021 - 2033)
• 1st Generation
• 2nd Generation
• 3rd Generation
• Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
• Oral
• Injectable
• Others (Nasal, etc.)
• Age Group Insights (Revenue, USD Bn, 2021 - 2033)
• Pediatric
• Adults
• Geriatric
• Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
• Pfizer Inc.
• Sumitomo Pharma Co., Ltd.
• Novartis AG
• Abbott
• GSK plc.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Takeda Pharmaceutical Company Limited
• Marinus Pharmaceuticals, Inc
• Eisai Co., Ltd
• DAIICHI SANKYO COMPANY, LIMITED
• Mylan N.V.
• Reddy's Laboratories Ltd
• Sun Pharmaceutical Industries Ltd.
• Neurelis, Inc.
• Supernus Pharmaceuticals, Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Epilepsy Drugs Market, By Type of Epilepsy
  • Epilepsy Drugs Market, By Drugs
  • Epilepsy Drugs Market, By Route of Administration
  • Epilepsy Drugs Market, By Age Group
  • Epilepsy Drugs Market, By Distribution Channel
  • Epilepsy Drugs Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Epidemiology
• Pipeline Analysis

4. Epilepsy Drugs Market, Type of Epilepsy, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Focal Epilepsy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Generalized Epilepsy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Reflex Epilepsy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Others (Progressive Myoclonic Epilepsy, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

5. Epilepsy Drugs Market, By Drugs, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• 1st Generation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• 2nd Generation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• 3rd Generation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

6. Epilepsy Drugs Market, By Route of Administration, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Injectable
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Others (Nasal, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Epilepsy Drugs Market, By Age Group, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Pediatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Adults
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Geriatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

8. Epilepsy Drugs Market, By Distribution Channel, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

9. Epilepsy Drugs Market, By Region, 2021 - 2033, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2026,2028 & 2033, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, Type of Epilepsy, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Drugs, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, Type of Epilepsy, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Drugs, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, Type of Epilepsy, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Drugs, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, Type of Epilepsy, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Drugs, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, Type of Epilepsy, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Drugs, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, Type of Epilepsy, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Drugs, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

10. Competitive Landscape

• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sumitomo Pharma Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Abbott
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GSK plc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Takeda Pharmaceutical Company Limited
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Marinus Pharmaceuticals, Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eisai Co., Ltd
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• DAIICHI SANKYO COMPANY, LIMITED
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Mylan N.V.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Reddy's Laboratories Ltd
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sun Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Neurelis, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Supernus Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us